A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity

Jun 18, 2015·
Garcia-Perez, J.
,
Staropoli, I.
,
Azoulay, S.
,
Heinrich, J.
,
Cascajero, A.
,
Colin, P.
,
Lortat-Jacob, H.
,
Arenzana-Seisdedos, F.
,
Alcami, J.
,
Kellenberger, E.
,
Lagane, B.
Abstract
Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. While MVC-resistant viruses have been identified in patients, it still remains incompletely known how they adjust their CD4 and CCR5 binding properties to resist MVC inhibition while preserving their replicative capacity. It is thought that they maintain high efficiency of receptor binding. To date however, information about the binding affinities to receptors for inhibitor-resistant HIV-1 remains limited.
Type
Publication
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity, Retrovirology 2015 12 (1), 50-